Home > Research > Publications & Outputs > Functional brain connectivity phenotypes for sc...

Electronic data

  • Dawson et al.,_2015_Accepted_Version

    Rights statement: The final, definitive version of this article has been published in the Journal, Journal of Psychopharmacology, 29 (2), 2015, © SAGE Publications Ltd, 2015 by SAGE Publications Ltd at the Journal of Psychopharmacology page: http://jop.sagepub.com/ on SAGE Journals Online: http://online.sagepub.com/

    Accepted author manuscript, 232 KB, PDF document

    Available under license: CC BY

Links

Text available via DOI:

View graph of relations

Functional brain connectivity phenotypes for schizophrenia drug discovery

Research output: Contribution to journalJournal article

Published
Close
<mark>Journal publication date</mark>02/2015
<mark>Journal</mark>Journal of Psychopharmacology
Issue number2
Volume29
Number of pages9
Pages (from-to)169-177
Publication statusPublished
Early online date7/01/15
Original languageEnglish

Abstract

While our knowledge of the pathophysiology of schizophrenia has increased dramatically, this has not translated into the development of new and improved drugs to treat this disorder. Human brain imaging and electrophysiological studies have provided dramatic new insight into the mechanisms of brain dysfunction in the disease, with a swathe of recent studies highlighting the differences in functional brain network and neural system connectivity present in the disorder. Only recently has the value of applying these approaches in preclinical rodent models relevant to the disorder started to be recognised. Here we highlight recent findings of altered functional brain connectivity in preclinical rodent models and consider their relevance to those alterations seen in the brains of schizophrenia patients. Furthermore, we highlight the potential translational value of using the paradigm of functional brain connectivity phenotypes in the context of preclinical schizophrenia drug discovery, as a means both to understand the mechanisms of brain dysfunction in the disorder and to reduce the current high attrition rate in schizophrenia drug discovery.

Bibliographic note

The final, definitive version of this article has been published in the Journal, Journal of Psychopharmacology, Vol. 29(2): 169-177, 2015, © SAGE Publications Ltd, 2015 by SAGE Publications Ltd at the Journal of Psychopharmacology page: http://jop.sagepub.com/ on SAGE Journals Online: http://online.sagepub.com/